Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool aims to predict where liver cancer spreads next

NCT ID NCT07444905

Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gives a risk score, but doctors still choose the actual care. The goal is to see if this approach leads to earlier detection of metastases and better survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more personalized and efficient surveillance strategy for liver cancer patients, potentially catching metastases earlier.
What could go wrong
This is an observational study, not a treatment trial. The tool may not improve outcomes or may be difficult to implement in real-world clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,523 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with hepatocellular carcinoma (HCC) without evidence of extrahepatic metastasis at baseline who are receiving standard-of-care management and undergoing prospective follow-up in routine clinical practice. Participants are enrolled in a prospective observational cohort to evaluate a machine learning-based risk assessment strategy for predicting extrahepatic metastasis and supporting risk-adapted surveillance.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of hepatocellular carcinoma (HCC) confirmed by histopathology or accepted radiologic criteria per international guidelines. * No evidence of extrahepatic metastasis at baseline evaluation. * Receiving standard-of-care management with planned longitudinal follow-up in routine clinical practice. * Availability of baseline clinical and imaging data required for risk assessment using the pre-specified machine learning model. * Ability to provide written informed consent, or inclusion under ethics committee-approved procedures. Exclusion Criteria: * Confirmed extrahepatic metastasis at enrollment (baseline). * History of other active malignancy within the past 5 years, except adequately treated non-melanoma skin cancer or in situ carcinoma. * Incomplete baseline clinical information that precludes model-based risk assessment. * Expected survival \< 3 months due to severe comorbidities. * Participation in an interventional clinical trial that may substantially alter follow-up strategy or metastasis assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Evaluation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Evaluation HCC - hepatocellular carcinoma Machine learning

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.